HIV pact marks licensing hat trick for Ascletis
This article was originally published in Scrip
Executive Summary
If evidence is needed that progressive Chinese bioventures are now looking outside the country to bolster their innovative pipelines, Ascletis Pharmaceuticals would provide a convincing case study.